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screening deoxyribonucleic acid (DNA) libraries with
immune sera or with immune T-lymphocytes [10, 11].
This study was designed to evaluate diagnostic sensi-
tivity and specificity of a novel tuberculosis complex-
specific recombinant protein of 34 kDa [12, 13]. An
enzyme linked immunosorbent assay (ELISA) test using
a fusion protein (MS2-34) comprising the 16 kDa NH2-
terminal fragment of the 34 kDa protein and an 11 kDa
fragment of the MS-2 polymerase fusion partner indicated
elevated anti-34 kDa antibody levels in the sera of
patients with TB. By combining this test with an ELISA
using the M. tuberculosis-specific recombinant 38 kDa
protein (p38) [14, 15], it was possible to diagnose TB in
AFB smearnegative patients with high sensitivity and
specificity.
Methods
Production of the recombinant MS2-34 fusion protein
Partial expression of the 34 kDa antigen gene [16]
was obtained as a 27 kDa fusion protein [17]. Briefly, a
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ABSTRACT: Tuberculosis (TB) serological testing with antigen complexes, although
very sensitive, is not always as specific due to reactive serum antibodies in patients
with inactive TB or nontuberculous infections. Since the use of recombinant M. tuber-
culosis proteins may enhance specificity, this study was designed to evaluate a novel
34 kDa tuberculosis complex-specific protein as a component of an antigen panel of
recombinant proteins.
Seventy patients with active TB (41 positive and 29 negative for acid-fast bacilli
(AFB) in sputum) were evaluated, in comparison with 30 tuberculin purified protein
derivative skin test positive (PPD+) and 30 PPD- normals, 20 subjects with inactive
TB and 20 PPD+ subjects with nontuberculous pneumonia as controls. Serum anti-
body levels were quantified using enzyme linked immunosorbent assay (ELISA) tests
with MS2-34, a fusion protein comprising the NH2-terminal 16 kDa of the 34 kDa
protein, a recombinant 38 kDa protein (p38), and PPD.
Using MS2-34 and p38 as an antigen panel in active TB patients yielded higher
sensitivity and negative predictive value (sensitivity 86%; negative predictive value
91%) than using PPD (sensitivity 66%; negative predictive value 81%). Importantly,
the MS2-34+p38 panel yielded a higher sensitivity (83%) than PPD (66%) in the
subset of AFB- active TB patients.
Thus, this novel protein increases sensitivity and specificity of serological testing
for TB when used in panels of recombinant proteins.
Eur Respir J., 1995, 8, 2008–2014.
Since the worldwide resurgence of tuberculosis (TB),
the development of rapid diagnostic tests is becoming
increasingly important. Up to 50% of M. tuberculosis
culture confirmed TB patients present with negative
acidfast bacilli (AFB) smears [1–4], and receive empirical
treatment until culture results are obtained. Rapid culture
methods, molecular assay, and serological assays may
all play important roles in securing a rapid diagnosis,
directing decision making on isolation and treatment of
patients, and on screening of contacts.
In recent years, serological tests for TB have been
developed using M. tuberculosis extracts, such as purified
protein derivative of the tuberculin (PPD), the antigen
complex A60 or purified antigens and recombinant pro-
teins [5, 6]. However, M. tuberculosis expresses broadly
cross-reactive antigens that may be recognized by non-
specific antibody reactions in: 1) healthy individuals [7];
2) M. tuberculosis-exposed contacts [7]; 3) persons with
inactive tuberculosis [5, 6, 8]; and 4) patients with myco-
bacteria other than tuberculosis (MOTT) infections [9].
Immunodominant M. tuberculosis proteins, which per-
form with higher sensitivity and specificity in diagnostic
serology, have been isolated in several laboratories by
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BamHI-EcoRI mycobacterial DNA fragment was inserted
in pBluescript (Stratagene, Cambridge, UK), recovered by
restriction enzyme digestion as a BamHI-HindIII frag-
ment, and reinserted into pEX34 c (Promega Corp., Madi-
son, WI, USA) to obtain a fusion protein (hereafter referred
to as MS2-34) comprising the NH2-terminal 142 amino
acids of the 34 kDa protein and an 11 kDa fragment of
the MS2 polymerase. The recombinant plasmid pSBc
was used to transform E. coli K12 DH Dtrp cells [18].
Bacterial cultures (400 mL of Luria-Bertani broth supple-
mented with 30 µg·mL-1 ampicillin) were induced to syn-
thesize the fusion protein by temperature shifting (30 to
42°C). Cells were collected after 150 min (10,000 × g for
15 min), resuspended in 3.2 mL of Tris-sucrose (50 mM
Tris, 25% sucrose, pH 8), incubated at 37°C for 30 min
(0.8 mL of 5 mg·mL-1 lysozyme and 0.8 mL of 0.5 M
ethylenediamine tetra-acetic acid (EDTA)), lysed with
Triton-X 100 (1% Triton 100, 50 mM Tris, 63 mM EDTA;
15 min at 0°C, 30 min at 37°C), sonicated and pelleted
(15,000 × g for 10 min). The pellet was washed in 1 M
urea (37°C for 30 min) and redissolved in the same buffer
before purification by preparative sodium dodecyl sul-
phate polyacrylamide gel electrophoresis (SDS-PAGE)
and electroelution. The fusion protein concentration and
purity were assessed by spectrophotometry (Lambda 5,
Perkin-Elmer & Co., GmbH, Uberfingan, Germany), by
Western blotting with the 34 kDa proteinspecific mono-
clonal antibody H61.3 [12], and by analytical SDS-PAGE
and silver staining (fig. 1).
Anti-MS2-34 serum levels
Immunoglobulin M and G (IgM and IgG) antibody
levels against the 34 kDa protein were quantified by
ELISA using the MS2-34 fusion protein (27 kDa) with
background subtraction of the MS-2 phage polymerase
fusion partner (MS2, 11 kDa). Briefly, MS2-34 (200 ng·well-1)
or an equimolar quantity of MS2 (81 ng·well-1) were
adsorbed on different wells of the microtitre plate for 1 h
and saturated with 3% bovine serum albumin (BSA)
(Sigma, St. Louis MO, USA) in phosphate buffer saline
(PBS). To quantify antibody levels, the binding of dupli-
cate serum samples (1:50 dilution, which was established
as the optimal dilution in preliminary experiments) was
revealed using biotin-conjugate anti-human IgM or IgG
antibodies (Sigma, St. Louis, MO, USA) and extravidin-
peroxidase (Sigma) with o-phenylenediamine (Sigma)
and H2O2 by spectrophotometry (490 nm, ETI-System
Fast Reader, Sorin Biomedica, Saluggia, Italy). Optical
density (OD) values were normalized using a pool of
four control sera (control), following the equation: (OD
sampleMS2-34/OD controlMS2-34) - (OD sampleMS2/OD con-
trolMS2). Tests with an intraduplicate error >20% were
discarded and repeated.
Anti-p38 serum levels
IgM and IgG antibody levels against the M. tuberculosis-
specific 38 kDa protein were quantified by ELISA tech-
nique using recombinant p38 (2 µg·well-1). The binding
of serum antibodies (1:100 dilution, which was established
as the optimal dilution in preliminary experiments) was
revealed using peroxidase conjugated anti- human IgM or
IgG antibodies (Sigma, St. Louis, MO, USA).
Anti-PPD serum levels
IgM and IgG antibody levels against PPD were quanti-
fied by ELISA technique using PPD (Statens Seruminstitut,
Copenhagen, DK; 40 µg·well-1) as described previously
Fig. 1. – A) Analytical sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with silver staining; and B) Western blot
with the monoclonal antibody H61.3 of the MS2-34 27 kDa fusion protein containing the NH2-terminal 98 amino acid of the 34 kDa tuber-
culosis complex protein. In each panel are shown the MS2-34 protein (lane 1) and the MS2 polymerase 11 kDa fusion partner (lane 2). Mole-
cular weight markers are shown to the left.
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[19]. Serum samples were used at the 1:500 dilution for
 IgM and 1:1,000 for IgG test, which were established as
the optimal dilution in preliminary experiments.
PPD skin testing was performed using 5 units of the
tuberculin purified protein derivative (PPD) (Sclavo,
Siena, Italy; or Parke-Davis, Morris Plains, NJ, USA). An
induration greater than 10 mm was scored as positive
[20].
Study populations
The study populations included PPD-negative and PPD-
positive healthy subjects, PPD-positive bacterial pneu-
monia patients and inactive TB patients. The healthy
control population included 30 PPD-positive non-bacille
Calmette Guérin (BCG)-vaccinated subjects (mean age
183 yrs, 11 males and 19 females, all Caucasians); and 30
PPD-negative subjects (mean age  174 yrs, 13 males and
17 females, all Caucasians) without a history of TB.
A group of 20 PPD-positive individuals affected by
nontuberculous bacterial pneumonia (mean age 3811
yrs, 12 males and 8 females) was also evaluated, since
the discrimination of bacterial pneumonia from TB by
means of immunological tests in individuals from moder-
ate TB prevalence areas may be confused by nonspecific
recall reactions. All subjects had negative M. tuberculosis
sputum cultures.
The nonactive TB population included 20 individuals
with chemotherapy-cured pulmonary TB (mean age 4213 yrs,
10 males and 10 females, all Caucasians), who were evalu-
ated after 12–24 months from the discontinuation of spe-
cific treatment. All had negative chest radiographs.
The active TB-affected population included 70 indi-
viduals with postprimary untreated pulmonary TB (mean
age 4117 yrs, 41 males and 29 females, 56 Caucasians, 1
African, 2 Asians, 11 Afro-Americans), who were evalu-
ated at the time of admission before the initiation of
antituberculous therapy. Average length of time with
symptoms before admission, that was evaluated on 34
subjects, was 3.32.9 months. All had M. tuberculosis
culture-positive sputum.
All patients were evaluated after obtaining informed
consent under protocols approved by the Ethics Committee
of the University of Modena (Italy) and the Georgetown
University (Washington DC, USA).
Statistical evaluation
Data are presented as meansstandard deviation of the
mean. ELISA tests were scored positive when individual
readings were greater than three standard deviations
above the control average (expected specificity 99.6%).
Comparisons between group antibody levels were
analysed using the Student's t-test. Comparisons between the
frequencies of positive and negative responders were
analysed using the Chi-squared test with Bonferroni cor-
rection. Sensitivity, specificity and predictive value were
evaluated as described by DANIEL and DEBANNE [5].
Results
Anti-MS2-34 levels in patients with active tuberculosis
Patients with active untreated TB had markedly higher
anti-MS2-34 IgM and IgG antibody levels (IgM,
0.500.31 and IgG, 0.380.26 ELISA units) compared to
PPD-positive normal controls (IgM, 0.120.05 and IgG,
0.110.04 ELISA units), or PPD-negative normal con-
trols (IgM, 0.070.03 and IgG, 0.080.04 ELISA units)
(p<0.01,) (fig. 2), and to pneumonia-affected individuals
(IgM, 0.110.04 and IgG, 0.120.03 ELISA units;
p<0.01) (fig. 2). Anti-MS2-34 IgM and IgG antibody
levels were also significantly higher in active TB patients
compared to individuals with inactive, chemotherapy-
cured TB (IgM, 0.060.04 and IgG, 0.090.11 ELISA
units; p<0.01) (fig. 2).
Sensitivity and specificity of the MS2-34 ELISA test
The IgM ELISA with MS2-34 (cut-off value 0.29
ELISA units) was as sensitive and specific, since the cut-
off value was above the normal range (table 1), as the
ELISA with p38 (cut-off value 1.10 ELISA units) and PPD
(cut-off value 0.94 ELISA units). In comparison to all
groups (PPD-negative and PPD-positive controls, patients
with bacterial pneumonia, and patients with inactive TB)
the anti-MS2-34 IgM specificity was 100% (99% confi-
dence interval (99% CI) 95–100%) i.e. similar to that of
the anti-p38 IgM test (100% (99% CI 95–100)) and the
anti-PPD IgM test (100% (99% CI 95–100)). Moreover,
since the IgM test MS2-34 (cut-off value 0.28 ELISA
units) was negative in almost all of inactive TB controls
(fig. 2b), the specificity of the IgG test with this protein
was as high as the IgM test. On the contrary, the p38
(cut-off value 0.76 ELISA units; fig. 2d) and the PPD
(cut-off value 0.67 ELISA units; fig. 2f) IgG test specifici-
ties were lower than the IgM tests (MS2-34 95% (99% CI
71–99); p38 40% (99% CI 16–68); p<0.01 compared to
MS2-34; PPD 25% (99% CI 7–53); p<0.001 compared to
MS2-34).
Sensitivity of the MS2-34 and p38 ELISA tests combined
When the two MS2-34 and p38 IgM ELISA tests were
evaluated as a test panel, combining the results obtained
for each antigen in separate assay plates, their rate of
positive tests (86% (33% to MS2-34 only; 21.5% to p38
only; 31.5% to both antigens)) was significantly higher
than for each antigen alone and for the PPD (p<0.02, all
comparisons) (table 1). They also had a higher negative
predictive value than PPD (MS2-34 and p38 combined
negative predictive value 91% (99% CI 82–96); PPD
81% (99% CI 71–88); p<0.03). As expected from the
lower p38 test specificity (see fig. 2), whilst the use of
the IgM test combination significantly improved the test
performance, the use of the two IgG tests combined did
yield the same sensitivity as the IgM test (81% (24% to
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MS2-34 only; 24% to p38 only; 33% to both antigens)) but
had lower specificity.
Evaluation of ELISA tests in active TB smear-negative
vs smear-positive and PPD-negative vs PPD-positive
patients
The MS2-34 ELISA test was positive in similar propor-
tions of AFB-negative and AFB-positive patients (p>0.6)
(table 2). Furthermore, when the MS2-34 and p38 IgM
ELISA tests were evaluated in combination, a higher pro-
portion of AFB smear-negative and smearpositive active
TB patients could be identified than with MS2-34, p38
and PPD alone (table 2).
The IgM MS2-34 ELISA test was positive in 75%
of PPD-negative subjects (p>0.2, compared to p38 and
PPD), and in 62% of PPD-positive TB patients (p>0.4,
compared to p38 and PPD). The IgG MS2-34 ELISA
Fig. 2. – Quantification of anti-p34 serum antibodies by ELISA with the MS2-34 recombinant fusion protein. On the ordinate (as normalized
ELISA units) are shown the levels of: a) IgM against MS2-34; b) IgG against MS2-34; c) IgM against p38; d) IgG against p38; e) IgM against
PPD; f) IgG against PPD. Cut-off values for each ELISA test (3 SD above the mean value of controls) are shown as a dotted line. Study groups
are shown on the abscissa. They were: PPD negative normal controls (1); PPD positive normal controls (2); patients with bacterial pneumonia
(3); individuals with inactive pulmonary tuberculosis (4); patients with AFB-positive active tuberculosis (5); and patients with AFB-negative
active tuberculosis (6). ELISA: enzyme-linked immunosorbent assay; IgM and IgG: immunoglobulin M and G; p38: a recombinant 38 kDa
protein; PPD: purified protein derivative skin test; AFB: acid-fast bacilli. For further abbreviations see legend to figure 1.
Table 1. – Sensitivity of IgM ELISA testing with MS2-34, p38
and PPD for the diagnosis of active tuberculosis
IgM: immunoglobulin M; ELISA: enzyme-linked immunosorbent
assay; MS2-34: a fusion protein comprising the NH2-terminal
98 amino acid of the 34 kDa tuberculosis complex protein;
p38: a recombinant 38 kDa protein; PPD- and PPD+: purified
protein derivative skin test negative and positive, respectively. *:
p<0.05 vs controls (all comparisons); §: p<0.01 compared to
IgM-MS2-34, IgM-p38 and IgM-PPD.
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test was positive in 50% of PPD-negative subjects (p>0.3,
compared to p38 and PPD) and in 57% of PPD-positive
TB patients (p>0.15, compared to p38 and PPD). In the
eight AFB-negative active TB patients with a negative
skin test, six were MS2-34 positive and seven (87%)
were MS2-34 and/or p38 positive. Out of 19 AFB-
negative/PPD-positives, 13 were MS2-34 positive and 16
(84%) MS2-34 and/or p38 positive (p>0.4, PPD-negative
vs PPD-positive).
Discussion
Since 1898, when a serological assay for the diagnosis
of TB was developed that showed 57% sensitivity and
89% specificity [21], tests with M. tuberculosis extracts,
sonicates and filtrates (including antigens such as PPD
and A60) have been described that showed sensitivities
between 49 and 95%, with specificities between 84
and 100% [5]. A number of M. tuberculosis purified anti-
gens, such as antigen 5, Lipo Arabino Mannan (LAM),
Sulpho Lipid-IV (SL-IV) and proteins of 10, 19, 24 and
30 kDa and several recombinant proteins including heat
shock protein 70 (HSP70), p38, p32, and p14, have also
been successfully employed [7, 22–27].
This study shows that the fusion protein MS2-34, as
obtained from the tuberculosis complex-specific 34 kDa
protein coding gene, performs in diagnostic serology
with high sensitivity and specificity. Furthermore, in the
context of serological studies with other purified pro-
teins in population groups of different geographical
background [28], the comparison of anti-MS2-34 anti-
body levels in patients of Caucasian or Africo-American
descent (data not shown), albeit preliminary, suggests
that recognition of this antigen is not limited by genetic
and racial factors.
The major advantage of using highly purified immun-
odominant reagents is that their use in multi-antigen tests
or in panels of tests may greatly improve upon diagnostic
sensitivity in comparison to antigen mixtures such as
PPD or A60. In this regard, BOTHAMLEY et al. [29] have
found that the combined use of tests with antigens, such as
p38, p19, p14, and LAM, and with monoclonal antibodies
against them may considerably improve diagnostic sensi-
tivity (up to 72%) compared to the single tests with LAM
(32%) and with p19 (58%). VERBON et al. [26] have
 obtained similar results with antigens of 10, 16, 24, 30, 38
and 70 kDa and the monoclonal antibody TB72 (specific
for the p38 protein [15]). They have shown that test
combinations, such as with the 10, 16, 24 kDa antigens
and the antibody TB72, could improve the diagnostic
sensitivity of each test. For example, the 10 kDa antigen
test showed 29% sensitivity, compared to 70% of the
combined tests.
Our observations with the use of both the MS2-34
and p38 recombinant proteins support these findings.
The combined MS2-34 and p38 assays' sensitivity and
specificity were very good even when specificity was con-
trolled against groups of PPD-positive healthy individu-
als, i.e. subjects naturally exposed to M. tuberculosis.
Furthermore, the test distinguished PPD-positive patients
with bacterial pneumonia presenting with a clinical
picture raising the suspicion of TB. The observation that
MS2-34 is specific for active TB, and it is not recognized
by IgG antibodies from patients with cured or inactive
disease is quite interesting, since discrimination of active
from inactive patients requires many immunological
markers [30]. However, the sensitivity of the MS2-34/p38
IgM test is as high as that of the MS2-34/p38 IgG
test. Thus, the use of the IgG test would not improve sensi-
tivity. whilst it may reduce specificity, since p38 is recog-
nized by IgG serum antibodies of patients with inactive
TB (this study and [31]). At the present time, we cannot
explain why the IgG recognizing MS2-34 decline more
rapidly than antibodies recognizing other proteins. In
the context that the 34 kDa protein is the gene product
of a mobile element [16], its expression may be expected
to be lower or more transient than that of constitutive pro-
teins [32]. It is, thus, possible that it may become rapidly
unavailable to the immune system with the reduction of
bacterial load.
With regard to the use of ELISA tests for antibodies
of different isotypes, it is worth mentioning the observa-
tion of TURNEER et al. [25], who found that the use of IgG
and IgA ELISA tests with the 32 kDa antigen did improve
the sensitivity of each test by 25 and 50%, respectively. In
this study, however, no significant increase in the sensitiv-
ity of IgM tests was observed when IgM and IgG results
were combined for either MS2-34 alone or both MS2-34
and p38.
Serological tests might play a major role in the setting
of the diagnosis of AFB-negative patients with suspect
TB, since in these subjects culture results may not be
available until 15–40 days after clinical presentation.
The data show that with the MS2-34 and p38 IgM ELISA
tests, TB can be diagnosed with 83% sensitivity and
greater than 95% specificity in AFB-negative patients.
Furthermore, IgM tests were found to be positive in 87%
of AFB-negative patients who also had a negative PPD
skin test, indicating a role for serology in immunological
diagnosis of TB.
With regard to the diagnosis of AFB-negative patients,
BOTHAMLEY et al. [29] found evident differences in
Table 2. – Sensitivity of IgM ELISA tests with MS2-34, p38,
PPD and the combination of MS2-34 and p38 in the diag-
nosis of tuberculosis in AFB-negative and AFB-positive
patients with active tuberculosis
AFB- and AFB+: acid-fast bacilli smear negative and positive.
respectively. For further abbreviations see legend to table 1.
*: p>0.40 compared to AFB smear-negatives; §: p<0.05 compared
to PPD, MS2-34 alone and p38 alone.
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the responses to p38 in AFB-negative compared to AFB-
positive patients. The present study, like the study by
TURNEER et al. [25] with p32, WILKINS and IVANYI [33] with
the anti-p38 TB72 antibody, and VERBON et al. [26] with
anti-p38 TB72 antibody, the 10, 16, 24, 30, 38 and 70 kDa
proteins showed similar sensitivity in AFB-negative and
AFB-positive patients. These comparisons, though, are
merely speculative if differences in each laboratories' pro-
ficiency with AFB smear techniques are not taken into
account [1–4].
Rapid molecular tests, such as the polymerase chain
reaction (PCR), are available for the diagnosis of TB
in AFB-negative patients [34, 35]. However, the applica-
tion of these tests is still limited to a small number of
laboratories. ELISA tests, although not as sensitive as
the molecular tests, are rapid, relatively inexpensive and
suitable for routine use. The use of multiple-antigen
ELISA tests with purified or recombinant proteins might
greatly enhance the power of serological diagnosis of TB
for those patients who may otherwise receive delayed
treatment.
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